Esperion Aiming For 50% Commercial Coverage For Nexletol

The company hopes to sidestep payer restrictions and patient abandonment by launching the cholesterol-lowering medicine at a palatable price point in line with where branded statins were before patent expiry.

Wooden boardwalk creates path through field of tall green grass leading to blue sky and puffy white cloud - horizontal — Esperion sees a clear path to market for Nexletol • Source: Shutterstock

Esperion Therapeutics Inc. has secured approval from the US Food and Drug Administration for its first drug – Nexletol (bempedoic acid) for high cholesterol – but successfully commercializing the drug in a therapeutic category that has burned far bigger and more experienced pharmaceutical players will be the next challenge.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

01 May 2025

• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.